Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

HROW sets ambitious price targets in a new 3-year plan while showcasing strong drug growth and leveraging a proven model for ...

Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

Harrow (NASDAQ:HROW) stock gains as Cantor Fitzgerald gives an Overweight rating for the company, citing a conservative outlook. Read more here.

Our tireless food critics and writers went into the tagliatelle trenches, emerging with a list of Greater Boston’s very best ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or "the Company") (NASDAQ: HROW) for ...

We feel now is a pretty good time to analyse Harrow, Inc.'s (NASDAQ:HROW) business as it appears the company may be on the cusp of a considerable accomplishment. Harrow, Inc., an eyecare ...

Get the latest Harrow, Inc. (HROW) stock news and headlines to help you in your trading and investing decisions.